-
Study aim
-
Safety and efficacy assessment of Synskin triple action eye contour cream (invisible) for reducing periorbital wrinkle, dark circle and puffiness
-
Design
-
It is a phase II interventional study as a non-randomized and before-after clinical study.20 healthy adult volunteers will participate enrolled in the study after signing informed consent.
-
Settings and conduct
-
The study will be conducted in Center for Research & Training in Skin Diseases and Leprosy. Participants will receive the eye contour cream, twice a day for 8 weeks on periorbital area. The assessments of area, volume and depth of periorbital wrinkles as well as skin biophysical parameters (skin hydration, trans epidermal water loss, erythema, melanin and skin elasticity) will be performed before intervention, 4 and 8 weeks after treatment.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Male or female aged 30-60 years,The presence of periorbital wrinkle, dark circle and puffiness, No change in life style during the study, Signed informed consent knowingly
Exclusion criteria: Critical untreated systemic disease in medical history, Any facial rejuvenation treatment, including treatment with topical or oral products or supplements during the last four weeks, Any facial rejuvenation treatment including rejuvenation devices or surgical procedures and Botox injections during the last four months, Sensitivity and allergy to the components of the formulation, Use of any eye cream or eye sunscreen cream during the last four weeks, Use of anti-wrinkle or brightening cleansers over the past four weeks, Pregnancy or lactation
-
Intervention groups
-
Using Synskin triple action eye contour cream twice a day for 8 weeks
-
Main outcome variables
-
Assessment of periorbital wrinkle, dark circle and puffiness by three independent physician using 0-3 scale